CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects
CNS Pharmaceuticals' Berubicin trial results show a favorable safety profile with no cardiotoxicity and comparable efficacy ...
BioSpace1d
AbbVie Lawsuit Alleges That Partner Genmab “Misappropriated” Trade Secrets
AbbVie claims that Genmab divulged key trade secrets to support the development of ProfoundBio’s investigational ...
GlobalData on MSN1d
Innovent Biologics doses first subject in trial of ovarian cancer therapy
Innovent Biologics has dosed the first subject in the Phase III HeriCare-Ovarian01 trial of IBI354 for treating PROC with ...
MedPage Today6h
FDA OKs New Option for Uncomplicated UTIs in Women, Girls
The FDA approved oral gepotidacin (Blujepa) for uncomplicated urinary tract infections (UTIs) in women and girls ages 12 ...
Fierce Biotech1d
AbbVie takes Genmab to court, accusing partner of being 'willfully blind' to ADC trade secret theft
AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the ...
BioWorld12d
Charles University and MFMER divulge new DNA topoisomerase II β inhibitors to treat cardiotoxicity
Scientists at Charles University and Mayo Foundation for Medical Education and Research (MFMER) have synthesized DNA topoisomerase II β inhibitors reported to be useful for the treatment of ...
Adcentrx Therapeutics To Showcase Novel STEAP1 And Napi2b Adcs With Oral And Poster Presentations At AACR 2025
The company will deliver an oral presentation on ADRX-0405, its clinical-stage STEAP1 ADC, and a poster presentation on ADRX-0134, its preclinical Na ...